Novel FAP-targeted Approach to Imaging Patients With or High-risk for Metastatic Prostate Cancer
Status: Recruiting
Location: See location...
Intervention Type: Radiation, Procedure
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age 18 years or older
• Able and willing to provide informed consent
• Known diagnosis of prostate cancer
• Scheduled for or recently performed (within 4 weeks) standard-of-care PSMA PET
• Optional: Scheduled for SOC biopsy of an established or suspected non-osseous, non-nodal metastases.
• Willing and able to undergo PET/MRI as part of this research
Locations
United States
Wisconsin
University of Wisconsin
RECRUITING
Madison
Contact Information
Primary
Radiology Studies
Radstudy@uwhealth.org
608-282-8349
Time Frame
Start Date: 2025-10
Estimated Completion Date: 2026-12
Participants
Target number of participants: 30
Treatments
Experimental: Fibroblast activation protein inhibitor (FAPI)
FAPI radiotracer will be used during PET
Related Therapeutic Areas
Sponsors
Leads: University of Wisconsin, Madison